Candel Therapeutics, Inc. CADL Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s retained earnings?
- Candel Therapeutics, Inc. (CADL) reported retained earnings of -$239.25M in Q1 2026.
- How has Candel Therapeutics, Inc.'s retained earnings changed year-over-year?
- Candel Therapeutics, Inc.'s retained earnings decreased by 29.4% year-over-year, from -$184.83M to -$239.25M.
- What is the long-term trend for Candel Therapeutics, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Candel Therapeutics, Inc.'s retained earnings has grown at a 39.1% compound annual growth rate (CAGR), from -$44.17M to -$230.39M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.